NYSE:CRMD
CorMedix Inc Stock News
$5.84
+0.470 (+8.75%)
At Close: May 03, 2024
CorMedix Inc. to Report First Quarter 2022 Financial Results and Provide a Corporate Update on May 12
12:30pm, Tuesday, 03'rd May 2022 GlobeNewswire Inc.
BERKELEY HEIGHTS, N.J. , May 03, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention
Inhibrx, Inc. (INBX) Soars 15%: Is Further Upside Left in the Stock?
10:32am, Tuesday, 03'rd May 2022 Zacks Investment Research
Inhibrx, Inc. (INBX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increa
CorMedix Inc. to Report First Quarter 2022 Financial Results and Provide a Corporate Update on May 12
08:30am, Tuesday, 03'rd May 2022
BERKELEY HEIGHTS, N.J. , May 03, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention an
CorMedix Inc. to Present at the 21st Annual Needham Virtual Healthcare Conference
08:30am, Monday, 04'th Apr 2022
BERKELEY HEIGHTS, N.J., April 04, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention a
CorMedix Inc Common Stock (CRMD) Q4 2021 Earnings Call Transcript
01:30am, Wednesday, 30'th Mar 2022 The Motley Fool
CRMD earnings call for the period ending December 31, 2021.
CorMedix (CRMD) Reports Q4 Loss, Tops Revenue Estimates
09:55pm, Tuesday, 29'th Mar 2022 Zacks Investment Research
CorMedix (CRMD) delivered earnings and revenue surprises of 9.09% and 40%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
CorMedix Inc. (CRMD) CEO Matt David on Q4 2021 Results - Earnings Call Transcript
09:44pm, Tuesday, 29'th Mar 2022
CorMedix Inc. (CRMD) CEO Matt David on Q4 2021 Results - Earnings Call Transcript
CorMedix Inc. Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update
08:01pm, Tuesday, 29'th Mar 2022 GlobeNewswire Inc.
Conference Call Scheduled for Today at 4:30 p.m. Eastern Time Conference Call Scheduled for Today at 4:30 p.m. Eastern Time
CorMedix (CRMD) Reports Q4 Loss, Tops Revenue Estimates
07:33pm, Tuesday, 29'th Mar 2022
CorMedix (CRMD) delivered earnings and revenue surprises of 9.09% and 40%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
The Daily Biotech Pulse: Sanofi-IGM Ink Antibody Drug Collaboration; NeoGenomics Sinks On CEO Departure, Q1 Warning; Decision Day For Akebia
11:41am, Tuesday, 29'th Mar 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Pfizer Announces Positive Results From Second Late-Stage Study Of Ulcerative Colitis Drug
Pfizer, Inc.
CorMedix Inc. Announces FDA Acceptance of Resubmission of New Drug Application for DefenCath
12:30pm, Monday, 28'th Mar 2022 GlobeNewswire Inc.
BERKELEY HEIGHTS, N.J., March 28, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention
Adma Biologics (ADMA) Reports Q4 Loss, Tops Revenue Estimates
09:35pm, Thursday, 24'th Mar 2022 Zacks Investment Research
Adma Biologics (ADMA) delivered earnings and revenue surprises of 10% and 1.47%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
CorMedix (CRMD) Stock Jumps 14.8%: Will It Continue to Soar?
12:59pm, Thursday, 24'th Mar 2022 Zacks Investment Research
CorMedix (CRMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
CorMedix (CRMD) Stock Jumps 14.8%: Will It Continue to Soar?
10:32am, Thursday, 24'th Mar 2022
CorMedix (CRMD) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
CorMedix Inc. to Report Fourth Quarter and Fiscal Year 2021 Financial Results and Provide a Corporate Update on March 29
08:30am, Tuesday, 22'nd Mar 2022
BERKELEY HEIGHTS, N.J., March 22, 2022 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention a
